News

Today, we’re thrilled to share a major milestone for Humane Genomics: we’ve partnered with Genezen to begin process transfer and cGMP (Current Good Manufacturing Practice) manufacturing of our lead oncolytic virus candidate for hepatoblastoma. This marks a big step forward in our mission to bring precision-engineered viral therapies to patients with cancer. Genezen is a leading viral vector CDMO with state-of-the-art facilities in Indianapolis and Lexington. Their deep expertise in viral vector process development and cGMP production makes them an…

We recently had the opportunity to attend the 2025 American Association for Cancer Research (AACR) conference in Chicago. It is one of the largest and most prestigious gatherings in the world for cancer researchers, clinicians, and biotech companies. It was an invaluable experience—an opportunity not only to present our latest findings but also to connect with peers and explore the exciting evolution of oncolytic viral therapies (OVTs). Here’s a recap of the key trends we observed and how they align…

Today, the 2024 Nobel Prize in Medicine was awarded to Victor Ambros and Gary Ruvkun for their groundbreaking discovery of microRNAs (miRNAs). This discovery has transformed our understanding of how cells regulate genes and opened new possibilities for diagnosing and treating diseases. But what exactly are miRNAs, and why are they so significant? What Are miRNAs?  miRNAs are tiny pieces of RNA, typically about 22 nucleotides long, that act as master regulators in cells. They don’t code for proteins themselves…